As of Jan 17, 2025, AstraZeneca PLC Intrinsic Value is $30.1. This suggests it may be overvalued by 54.8% compared to its current price of around $66.6.
As of Jan 17, 2025, AstraZeneca PLC's Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $66.6, using a discount rate of N/A and terminal growth rate of 3.0%.
AstraZeneca PLC is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $30.1, compared to a market price of around $66.6. This suggests a potential overvaluation of 54.8%.